nuvel ad: I am a neurologist. I prescribed propranolol 1,134 times. I counted the number after I came home from Japan.

I have been a neurologist for twenty-three years. I have prescribed propranolol to essential tremor patients 1,134 times. I know that number because I went back and counted it after I came home from Japan, and I needed to know how many people I had given the same incomplete answer to. I am going to tell you what I found there. Not because it is comfortable for me to say. Because I spent twenty-three years watching patients manage a condition I never fully understood, and I am done leaving that unsaid. My name is Dr. Michael Anderson. I am a board-certified neurologist. I have been practicing movement disorders for two decades and I have treated essential tremor longer than most of my colleagues because I have always believed it deserved more serious attention than it gets. It is the most common movement disorder in the world. More common than Parkinson's. More common than MS. It affects an estimated seven million Americans and the standard of care for it has not meaningfully changed since the 1970s. I want to tell you why I went to Japan, and what I found when I got there. First I need to tell you about my patients. Because this story starts with them, not with me. I want to tell you about a woman I will call Ruth. Ruth came to me at 63 with hand tremors that had been progressing for eleven years. She had been on propranolol for six of those eleven years, prescribed by her previous neurologist, dose escalating every eighteen months as the tremor outpaced the medication. By the time she sat across from me she was at 120mg daily and her resting blood pressure was low enough that she got dizzy when she stood up. Her husband had started walking behind her on stairs. I reviewed her chart, examined her, and I did what any neurologist would do. I discussed switching from propranolol to primidone, which works through a different mechanism and sometimes catches patients who have plateaued on beta blockers. Ruth looked at me for a moment and said, Dr. Anderson, I need you to tell me something honestly. Is there anything that actually fixes this, or are we just going to keep adjusting medications until I can't feel my legs? I told her what I was trained to tell her. That essential tremor is a chronic progressive condition. That the goal of treatment is management. That we would find the combination that worked best for her particular case. She nodded. She filled the primidone prescription. She came back four months later with the specific cognitive fog that primidone produces in a significant percentage of patients, the one that feels like thinking through gauze, the one that I had described in medical school as transient and that my patients consistently describe as permanent. She told me she had stopped finishing her sentences at work. She told me she had stopped going to her book club because she couldn't hold the conversation the way she used to. She asked me if there was anything else. I told her we could try topiramate, or discuss referral for botox injections, or eventually evaluate her candidacy for focused ultrasound. She looked at me the way patients look at you when they understand that the list you're reading from is the whole list. She said thank you, Dr. Anderson. She shook my hand. She did not come back. I have thought about Ruth more than I have thought about most patients. Because she asked me the right question and I gave her the only answer I had, and the only answer I had was not good enough. I want to tell you about a man I will call Gerald. Gerald was 71. Essential tremor affecting hands and head, diagnosed fourteen years prior. He had tried propranolol and stopped after eight months because his blood pressure dropped too low. He had tried primidone and stopped after six months because the sedation was making it impossible for him to drive, and driving was how he got to his grandchildren. He had tried gabapentin, which gave him mood instability severe enough that his wife called my office. He had tried topiramate and lost twenty pounds he did not have to lose. He came to me because he had been through four medications in fourteen years and was looking for a fifth, and something in him knew before he sat down that there wasn't one that was going to be different. I had no fifth medication to offer him. What I did not know at the time, and what I am going to tell you now, is why. I went to Japan in the spring of two years ago. I want to be honest about why. I had been thinking about Ruth for three years. I had been thinking about Gerald for two. And I had found a paper, buried in the movement disorders literature, that contained a single statistic I could not explain and could not stop thinking about. Essential tremor is more than forty times more common in the United States than in Japan. Not somewhat more common. Forty times. Per hundred thousand adults, adjusted for age, accounting for diagnostic differences. The gap is real, it is documented, and it has been sitting in the neurological literature for years without generating the attention it deserves. I had read that statistic and immediately reached for the explanations that make the gap comfortable. Genetic differences in the Japanese population. Diagnostic criteria variations. Underreporting. I reached for those explanations because they require nothing of me. If it is genetics, it is not my problem to solve. If it is reporting, the patients I see are being treated correctly. But I knew the explanations were inadequate. Because Japanese Americans, raised on Western diets in Western environments, develop essential tremor at rates that look far more like American rates than Japanese ones. The protection, whatever it is, does not travel in the genes. It travels in the life. So I went to find out what the life was. I spent three weeks in Japan. I visited movement disorder clinics in Tokyo and Osaka. I sat with neurologists who had been treating tremor patients for decades. I visited a rehabilitation institute outside Kyoto where the director had spent thirty years documenting outcomes in ET patients managed without Western pharmaceutical protocols. And I sat in the kitchen of a 79-year-old retired hospital pharmacist in Osaka named Haruki Nakamura, whose wife had been diagnosed with essential tremor at 52 and who had, at 79, a tremor that her own neurologist described as clinically insignificant. I asked him what he attributed that to. He looked at me the way someone looks at you when you have asked a question that seems obvious to them. He said, doctor, we treat the neurotransmitter. You treat the symptom. That is the whole difference. I asked him what he meant. He said: sit down. I will make tea. This will take a while. Here is what Haruki told me, and what the three weeks of clinic visits confirmed, and what I have spent the two years since coming home trying to understand why my training never covered. Essential tremor is not, at its root, a movement problem. I know that sounds strange coming from a neurologist who has been treating it as a movement problem for twenty-three years. Stay with me. Your cerebellum, the structure at the base of your brain that coordinates voluntary movement, does not operate in isolation. It runs on a circuit, a loop of neurons connecting the cerebellum to the thalamus and back out to the motor cortex. When that circuit is healthy, it sends clean signals. Your hand reaches for a glass and the cerebellum calibrates the movement precisely, in real time, and the result is a hand that does what you told it to. In essential tremor, that circuit oscillates. Instead of one clean signal, it generates a rhythmic series of signals, several times per second, that produce the rhythmic shaking you can see. The circuit is stuck in a loop it cannot exit. Now. What keeps that circuit from looping? The answer is neurotransmitters. Specifically the inhibitory neurotransmitters. The chemical signals that your neurons use to say stop. To apply the brake. To dampen the circuit when it is running too fast. The primary inhibitory neurotransmitter in the cerebellar circuit is GABA. When GABA signaling in the cerebellum is adequate, the circuit is regulated. The brake holds. The tremor is suppressed or absent. When GABA signaling is deficient, the brake slips. The circuit runs. The hand shakes. This is not a hypothesis. GABA deficiency in the cerebellar circuit has been documented in essential tremor patients in multiple peer-reviewed studies. The dentate nucleus, one of the deep cerebellar structures central to the tremor circuit, shows measurable reduction in GABA receptors in ET patients. The reduction correlates with tremor severity. This is established in the literature. And here is the thing that Haruki said that I could not shake. We do not give you anything for GABA deficiency. We do not give you anything that rebuilds the inhibitory brake. Propranolol suppresses the adrenergic amplification of the tremor. Primidone sedates the circuit broadly. Neither of them touches GABA production. Neither of them addresses why the brake is slipping in the first place. We are turning down the volume on a circuit that is misfiring because the chemical that regulates it is insufficient, and we are doing nothing about the insufficiency. I sat in that kitchen and thought about Ruth. She asked me if anything actually fixes this. I had told her no. And I had told her no not because nothing fixes it, but because I had never been trained to look at what was broken in the first place. Haruki walked me to his wife's cabinet after the tea. Three small bottles, lined up at the front of the shelf where she could see them every morning. He tapped each one in turn. B12. B6. B1. He said: in Japan we have known for fifty years that these three vitamins are what the nervous system uses to produce and maintain the neurotransmitters that regulate motor circuits. We call them the neurotropic vitamins. Not because of the name on a label. Because they act specifically on nerve tissue, on the chemistry of the nerve itself, in ways that no other nutrient class does. He said: your country knows about these vitamins in the context of deficiency disease. You test for B12 deficiency. You treat pernicious anemia. But deficiency disease is the extreme end of a spectrum. A person can have B12 levels well above the deficiency threshold and still have nerve cells that are running short of what they need to produce GABA, maintain myelin, and keep the circuits that regulate movement from oscillating. He said: we prescribe methylcobalamin, the active form of B12, as a pharmaceutical for nerve conditions here. Not a supplement. A medication. We have been doing this since 1973. And the reason we use the active form, methylcobalamin, rather than what you sell in your pharmacies, cyanocobalamin, is that cyanocobalamin requires conversion in the body before it can be used by nerve tissue. That conversion is inefficient. For a significant portion of patients it barely happens. So they have a normal B12 on their lab report and nerve cells that are metabolically starved, because the test and the tissue are measuring different things. He paused. He said: and the reason your country's B12 supplements do not work for nerve conditions is not because B12 does not work. It is because you are using the wrong molecule, at inadequate doses, absorbed at under one percent through a gut that is not designed to absorb it in that form, and you are calling that B12 supplementation. I drove back to Tokyo that night and I read until 3am. Here is the mechanism that Haruki was describing, and that the literature he pointed me to confirmed. GABA is not stored somewhere waiting to be used. Your nerve cells synthesize it continuously from a precursor called glutamate. That synthesis requires an enzyme. That enzyme requires a cofactor to function. The cofactor is B6. In its active form, pyridoxal-5-phosphate, which clinicians call P5P. Without adequate P5P, the enzyme runs slow. GABA synthesis drops. The inhibitory brake on the cerebellar circuit weakens. The circuit oscillates. The tremor appears, or worsens. This is the mechanism. Not a theory. A documented enzymatic pathway. The reason a GABA deficit can develop in the nervous system without any obvious disease process is that P5P depletion can happen gradually, over years, without producing the dramatic deficiency symptoms that would send someone to a doctor. The myelin connection runs alongside this. Every neuron in that cerebellar circuit is wrapped in a protective coating called myelin. The myelin sheath is what allows the signal to travel fast and clean. Without it, the signal degrades, frays, carries noise it was never meant to carry. A circuit running on degraded myelin is a circuit that is prone to oscillation. Your body maintains that myelin coating continuously. It degrades and is rebuilt, constantly, by specialized cells called oligodendrocytes. The raw material those cells build myelin from is something called sphingomyelin, and the synthesis of sphingomyelin requires methylation, a specific chemical process that runs throughout your nervous system and depends heavily on one molecule. Methylcobalamin. Active B12. And the energy required to run that myelin maintenance process, to power the oligodendrocytes and the neurons through the metabolic demands of constant repair, comes from a coenzyme your nerve cells require to produce ATP. That coenzyme is thiamine in its fat-soluble form, benfotiamine. Not the water-soluble thiamine hydrochloride in most B complexes, which stays in the bloodstream and does not penetrate nerve tissue. Benfotiamine, which crosses into the nerve cell and is available where the energy production actually happens. Three vitamins. Three points in the same chain. B6 as P5P produces the GABA that regulates the circuit. B12 as methylcobalamin provides the raw material to maintain the myelin that the circuit runs through. B1 as benfotiamine provides the energy the nerve cells need to do both. Miss any one of them and you get a fraction of the effect. A study published in 2024 in the journal Cells tested B12 alone against all three together on damaged nerve tissue. B12 in isolation was the least effective of the three nutrients tested. The combination was twenty-six times more effective than B12 alone, because each step of nerve maintenance depends on the one before it. This is why the B complex from the pharmacy didn't work for the patients I sent home with it. Not because the concept is wrong. Because the forms were wrong, the doses were inadequate, and the delivery never got the vitamins past the bloodstream and into the nerve cell where the work happens. I came home from Japan and I did something I had not done in twenty-three years of practice. I changed my protocol. I am still prescribing propranolol to patients who need immediate symptom management. I am not telling anyone to stop their medication. That is not what this is. The beta blockers manage the amplitude of the tremor while the nerve pathways that produce it are still being supplied inadequately. They do their job. They do not do the job that the neurotropic vitamins do, and the neurotropic vitamins do not do the job the beta blockers do. These are not competing treatments. They are addressing different problems. What I am doing differently is that I no longer end the appointment without addressing the nerve. I tell patients about the GABAergic deficit that research shows underlies essential tremor. I tell them what their neurons need to produce the inhibitory signals that regulate the tremor circuit. I tell them about the myelin and the three vitamins that support it. I tell them that Japan has been treating nerve conditions with these vitamins as clinical pharmaceuticals since 1973 and that the outcomes in ET patients managed this way have been documented for decades. And I tell them what Haruki told me. We are not offering you a cure. Essential tremor is a chronic condition and managing it is a lifelong process. What we are offering is the first intervention aimed at the chemistry that produces the tremor, rather than the tremor itself. Most patients find that the severity of the bad days decreases. That the baseline tremor is quieter. That the progression, which in untreated essential tremor advances reliably at one to four percent per year, slows in a way they can feel. Some patients report that they go periods of days where the tremor is barely present. I am careful not to promise this because it is not universal. What I can tell you is that in the patients I have been managing with the neurotropic vitamins alongside their standard care over the past eighteen months, not one of them has asked me to escalate their medication dose. That is a first in twenty-three years of treating this condition. The formula I recommend, and that I take myself every morning, is Nuvel. I take it myself not as a performance of belief but because I am 57 years old and I have a family history that includes my father's tremor, which started at 61 and was significant by 65. I am not willing to wait until I am sitting across from a colleague asking the question Ruth asked me. Nuvel contains all three neurotropic vitamins in the active forms that actually reach nerve tissue. Methylcobalamin at 5,000 micrograms. Not cyanocobalamin. The form that does not require conversion, that the oligodendrocytes can use directly to build and maintain myelin. Benfotiamine at a clinical dose. The fat-soluble B1 that crosses into nerve tissue. Not thiamine hydrochloride, which stays in the bloodstream. P5P at two milligrams, the therapeutic dose of active B6. Not pyridoxine hydrochloride, which at the 50 to 100 milligram doses sold in most nerve supplements causes peripheral nerve damage. There are products in every pharmacy in this country marketed for nerve health that are neurotoxic at the dose on the label. I have diagnosed B6 toxicity neuropathy in my own patients twice. Both times they had purchased a nerve support supplement. The delivery is liposomal, sublingual. Under the tongue, ninety seconds, once a day. I need to explain why the delivery matters, because this is the piece most people miss and it is the reason the B complex from the pharmacy shelf does nothing measurable for nerve conditions. Your gut absorbs oral B12 at under one percent of the dose. Under one percent. The fraction that enters your bloodstream still has to cross into the nerve cell itself to do anything, and oral B12 does not reliably accomplish that crossing. In Japan, methylcobalamin for nerve conditions is given by injection because the oral form does not arrive. The needle bypasses the gut and delivers the vitamin directly into circulation at therapeutic concentrations. A liposome does the same job without the needle. A liposome is a sphere built from phospholipids, the same material your cell membranes are made of. The vitamins are sealed inside. When absorbed under the tongue, the liposome bypasses the gut entirely. When it reaches a nerve cell membrane, the two membranes are made of the same material. They fuse. The vitamins are released directly inside the cell. Not in your bloodstream where a lab test can see them and call your levels normal. Inside the nerve cell where the myelin is built and where the GABA synthesis runs. This is not a theoretical difference. It is the difference between a blood test that looks fine and a nerve that actually has what it needs to function. Ruth asked me if anything actually fixes this. I told her no, and I believed it, and I was wrong in a specific way that I think about more than I let on. I was right that nothing cures essential tremor. I was wrong that nothing addresses the root of it. Those are different statements and I had collapsed them into the same answer because the tools I had been given addressed neither, and the tools that address the root were never part of my training. Your neurologist is not withholding something. The pharmaceutical pipeline for essential tremor is thin because the disease is not fatal, does not generate the research funding that rarer more dramatic conditions generate, and has not attracted the attention it deserves given how many people it affects. Propranolol was approved for ET in 1967. The standard of care has added primidone since then and almost nothing else. The neurotropic vitamins were not part of my training because there is no patent on methylcobalamin. No pharmaceutical company funds a clinical trial for a molecule they cannot own for twenty years. The research sits in academic journals and in the clinical protocols of countries that approached nerve medicine differently, and it does not get a sales representative to walk it into my office. I walked into it myself. In a kitchen in Osaka, with tea I had not asked for, sitting across from a man who watched his wife's tremor stay clinically insignificant for twenty-seven years while he gave her three vitamins every morning because a pharmacist in Tokyo had told him to. He was not curing her. He was feeding the nerve what it needed to maintain itself. He was giving the circuit the GABA it needed to stay regulated. He was supplying the myelin the raw material to stay intact. He was doing the thing that my entire training had never told me to do. The thing that addresses the root. Nuvel. Liposomal Neurotropic B Vitamins. All three. Active forms. Clinical doses. Delivered into the nerve cell. One dose every morning. That is the protocol. 90-day money-back guarantee. If nothing has improved in three months, full refund. I have never once seen a pharmaceutical company offer to refund you if propranolol did not work. Think about what that tells you about who is confident in what. The medications I prescribed for twenty-three years addressed the tremor. This addresses the nerve. Those are not the same thing, and I spent twenty-three years not knowing the difference. 👉 https://trynuvel.com/products/vitamin-b-complex-liposomal P.S. I counted the propranolol prescriptions after I came home from Japan. 1,134. I did not count how many of those patients eventually stopped taking it because the side effects outweighed the benefit, because I did not have a way to track that. I know it was a significant number because I saw them in follow-up asking what else there was. I told them what else there was, and the list was short, and most of them left with it and I did not see them again. I am telling you what else there is now. It should have been on that list years ago. P.P.S. If your neurologist has told you that propranolol and primidone are the options and you have tried them and they have failed, you are not out of options. You are out of the options your neurologist was trained to offer. Those are different situations. The options your neurologist was not trained to offer are what I went to Japan to find, and they have been in clinical use there for fifty years, and they are available to you right now. P.P.P.S. The forms on the label matter more than the name on the label. Cyanocobalamin is not methylcobalamin. Pyridoxine hydrochloride at 100mg is not P5P at 2mg — it is the form and the dose that has caused nerve damage in patients I have treated in my own clinic who bought it to help their nerves. A generic B complex from a pharmacy shelf is not the neurotropic protocol. Do not let the wrong product be your evidence that this approach does not work.